LungLife AI, Inc.
("LungLife" or the "Company")
Block Listing Six Monthly Return
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:
| Name of applicant: | LungLife AI, Inc. | |||
| Name of scheme: | 2010 Stock Incentive Plan2020 Stock Incentive Plan2021 Omnibus Long-Term Incentive Plan | |||
| Number and class of securities originally admitted: | 1,356,139 common shares of US $0.0001 each | |||
| Date of admission: | 15 November 2021 | |||
| Period of return: | From: | 15 November 2023 | To: | 15 May 2024 |
| Balance of unallotted securities under scheme(s) from previous return: | 475,583201,374673,990 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | NILNILNIL | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | NILNILNIL | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 475,583201,374673,990 | |||
| Total number of securities in issue at the end of the period | 30,658,603 | |||
| Name of contact: | David Anderson, Chief Financial Officer |
| Telephone number of contact: | +44 (0)20 7933 8780 or lunglifeai@walbrookpr.com |
For further information please contact:
| LungLife AI, Inc. | www.lunglifeai.com |
| Paul Pagano, CEO | Via Walbrook PR |
| David Anderson, CFO | |
| Investec Bank plc (Nominated Adviser & Broker) | Tel: +44 (0)20 7597 5970 |
| Virginia Bull / Cameron MacRitchie / Lydia Zychowska | |
| Goodbody (Joint Broker) | Tel: +44 (0) 20 3841 6202 |
| Tom Nicholson / Cameron Duncan | |
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com |
| Alice Woodings / Phillip Marriage | Mob: 07407 804 654 / 07867 984 082 |
About LungLife
LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com
Our Purpose is to be a driving force in the early detection to lung cancer. Our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.
"*" indicates required fields
LungLife AI licensure/accreditation information posted here.